Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial

Trial Profile

Efficacy of ALK house dust mite allergy immunotherapy tablet in subjects with house dust mite induced asthma. The MITRA Trial

Completed
Phase of Trial: Phase III

Latest Information Update: 08 Mar 2017

At a glance

  • Drugs House dust mite allergy immunotherapy-ALK Abello (Primary)
  • Indications Allergic asthma
  • Focus Registrational; Therapeutic Use
  • Acronyms MITRA
  • Sponsors ALK-Abello
  • Most Recent Events

    • 26 Apr 2016 Results published in the JAMA: the Journal of the American Medical Association
    • 26 Apr 2016 Results published in The Journal of the American Medical Association, according to an ALK-Abello media release.
    • 26 Apr 2016 Results published in an ALK-Abello media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top